Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.43 |
| ▸ | HTR3B | O95264 | 3/20 | 0.43 |
| ▸ | HTR3A | P46098 | 3/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27702525 | 0.92 | SLC6A7 (0.63) | SLC6A7TRPV1NAMPTKDM4EALDH1A1 | |
| SCHEMBL9557856 | 0.87 | HTR3A (0.53) | SLC6A7TRPV1KDM4EALDH1A1HTR3E | |
| SCHEMBL6348921 | 0.81 | HTR3E (0.47) | SLC6A7TRPV1HTR3EHTR3BHTR3A | |
| SCHEMBL4813898 | 0.81 | SLC6A7 (0.66) | SLC6A7TRPV1NAMPTKDM4EALDH1A1 | |
| Biphenyl SCHEMBL27685969 | 0.80 | SLC6A7 (0.60) | SLC6A7ALDH1A1HSD17B10HTR3EHTR3B | |
| SCHEMBL21075073 | 0.79 | AVPR1A (0.56) | — | |
| SCHEMBL5462615 | 0.77 | HTR3E (0.77) | KDM4EALDH1A1HPGDHSD17B10HTR3E | |
| SCHEMBL5317665 | 0.76 | SLC6A7 (0.53) | SLC6A7TRPV1NAMPTKDM4ERIPK1 | |
| SCHEMBL20140603 | 0.76 | TRPV1 (0.57) | SLC6A7TRPV1ALDH1A1 | |
| SCHEMBL5317667 | 0.76 | SLC6A7 (0.53) | SLC6A7TRPV1NAMPTKDM4ERIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| US-20100311763-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | NOVARTIS PHARMA AG (US) | 2010-12-09 | — | — | US | disclosed |
| US-20080280916-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280916-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MC1R, CASP9, PRDX5 | SLC6A7 3063/4885TRPV1 1762/4885NAMPT 2121/4885 |
| US-20100311763-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MC1R, CASP9, PRDX5 | SLC6A7 3063/4885TRPV1 1762/4885NAMPT 2121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.